Enzyme engineering firm Codexis has entered into a commercial and manufacturing license agreement with Alphazyme for multiple enzymes from Codexis’ life science enzyme portfolio.
According to a statement from Codexis, the nonexclusive license includes the firm's HiFi DNA Polymerase, HiTemp Reverse Transcriptase, and HiRev Isothermal Polymerase, along with other enzymes designed for genomics and diagnostic applications.
Alphazyme, a business of life sciences company Maravai, collaborates with the manufacturers of nucleic acid synthesis and detection platforms to produce custom molecular biology enzymes on an industrial scale.
Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. Other terms of the arrangement were not disclosed.
The licensing agreement is part of Codexis’ strategy to divest itself of non-core assets to shift focus to its pharmaceutical manufacturing business and its proprietary Enzyme Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform. The ECO Synthesis platform is designed to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route, according to the firm.
